國家衛生研究院 NHRI:Item 3990099045/7346

NHRI > Institute of Biotechnology and Pharmaceutical Research > Ching-Chuan Kuo > Periodical Articles > Item 3990099045/7346

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7346

Title:	Heart failure and angiotensin II modulate atrial Pitx2c promotor methylation
Authors:	Kao, YH;Chen, YC;Chung, CC;Lien, GS;Chen, SA;Kuo, CC;Chen, YJ
Contributors:	Institute of Biotechnology and Pharmaceutical Research
Abstract:	Heart failure (HF) can increase atrial fibrillation and induce cardiac hypermethylation. The homeobox gene Pitx2c plays important roles in the genesis of atrial fibrillation and the promoter region of Pitx2c contains cytosine-phosphate-guanine islands. Therefore, epigenetic modification by hypermethylation may reduce Pitx2c expression in atrial myocytes. The aim of the present study were to evaluate whether HF can modulate DNA methylation of Pitx2c and the potential mechanisms involved. We used real-time polymerase chain reaction, immunoblotting and pyrosequencing to investigate RNA and protein expression, as well as the methylation of Pitx2c, in isoproterenol-induced HF, healthy rat left atria and in HL-1 cells with and without (control) exposure to angiotensin (Ang) II (0.1 and 1mol/L) or isoproterenol (1 or 10mol/L) for 24h. The HF atrium exhibited increased Pitx2c promoter methylation with increased DNA methyltransferase (DNMT) 1 and decreased Pitx2c protein levels compared with the normal atrium. Angiotensin II (0.1 and 1mol/L), increased Pitx2c promoter methylation in HL-1 cells with increased DNMT1 and decreased Pitx2c and Kir2.1 protein levels compared with control cells. These effects were attenuated by the methylation inhibitor 5-aza-2-deoxycytidine (0.1mol/L) and by the AngII receptor blocker losartan (10mol/L). However, isoproterenol (1 and 10mol/L) did not change the expression of the Pitx2c, DNMT1 and Kir2.1 proteins. In conclusion, HF induces Pitx2c promoter hypermethylation and AngII may contribute to the hypermethylation in HF.
Date:	2013-06
Relation:	Clinical and Experimental Pharmacology and Physiology. 2013 Jun;40(6):379-384.
Link to:	http://dx.doi.org/10.1111/1440-1681.12089
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0305-1870&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000319522900006
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84878389670
Appears in Collections:	[Ching-Chuan Kuo] Periodical Articles

Files in This Item:

File	Description	Size	Format
ISI000319522900006.pdf		590Kb	Adobe PDF	551	View/Open

Loading...